Benitec Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. (BNTC) on July 25, 2023. The filing reports a material corporate action involving a reverse stock split of the Company's common stock, effective July 26, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structural amendment to the Company's capitalization.
Material Changes
- Reverse Stock Split: A 1-for-17 reverse stock split was effected. Every 17 shares of pre-split common stock were converted into one share of post-split common stock.
- Effective Date: The split became effective at 12:01 a.m. Eastern Time on July 26, 2023.
- Trading Details: The trading symbol remains "BNTC" on The Nasdaq Capital Market. The CUSIP number changed to 08205P209.
- Fractional Shares: No fractional shares were issued; holdings were rounded up to the nearest whole number.
- Adjustments: All outstanding options, pre-funded warrants, and warrants were adjusted proportionately.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on operational performance. The primary purpose of the split is to adjust the share price and structure, authorized by the Board of Directors under discretion granted by stockholders at the December 7, 2022 annual meeting. The Company noted that the split is subject to Nasdaq approval for trading on an adjusted basis.
Investor Verification Checklist
- Verify the new CUSIP number (08205P209) for the common stock.
- Confirm the adjusted share count in brokerage accounts following the 1-for-17 conversion.
- Review the adjustment terms for any outstanding options or warrants held.
- Check the Company's active registration statements (S-1 and S-8) for automatic incorporation of this split data.